Fred Hutch is changing the way cancer is treated

Integrated Research Centers

Immunotherapy
Pathogen-Associated Malignancies

Driven by science to benefit patients
Adoptive T cell therapies – immune cells that fight cancer

1. Isolate T cells
2. Remove tumor
3. Expand
4. Single dose
5. Genetically modify surface receptors

TCR

CAR
Clinical trials of a living drug

Isolate T cells

CAR expression and expansion
15 days

Patient chemotherapy

Patient CAR T cell infusion

Monitor CAR T cells in the blood

T Cell

CAR

CD19

Tumor Cell
An incredibly low dose
Using immunotherapeutic approaches to treat Merkel Cell Carcinoma—a skin cancer twice as deadly as malignant melanoma

Maximum percent change from baseline of target lesions in 24 patients undergoing Pembrolizumab treatment. Horizontal dashed lines denote partial response (RECIST v 1.1 criteria). Patients positive for MCPyV are in blue, in red, negative.

- Pembrolizumab was listed in 2017 NCCN Guidelines for MCC
- Avelumab was first-ever therapy FDA-approved to treat metastatic MCC in March 2017
Thank you!